KAMURAN İBİŞ, RASİM MERAL, AHMET KARADENİZ, MURAT GÜVELİ, SELNUR ÖZKURT, BİLGE BİLGİÇ, MUSA ALTUN
Turkish Journal of Oncology - 2016;31(2):39-44
OBJECTIVE Neurocytoma is a rare tumor of central nervous system (CNS). The present study is an analysis of benefits and risks of radiotherapy (RT) after surgery. METHODS Following a retrospective evaluation of 2186 CNS tumors treated at the university oncology institute, 6 cases of neurocytoma were found. These 6 cases were analyzed according to patient sex, age, location of tumor, treatment type, and survival. RESULTS Median patient age was 40 years. Four tumors were centrally located, and the remaining 2 tumors were located in the extraventricular region. All of the patients received 50-60 Gy of conventional irradiation. Median length of follow-up was 51 months (range: 15-88 months). In this study, 5-year survival rate was 60%. CONCLUSION Primary treatment for neurocytoma is surgery. RT is suggested only for subtotally resected tumors, recurrent tumors, or tumors with atypical characteristics due to delayed side effects.
